Mechanisms and fitness costs of resistance to antimicrobial peptides LL-37, CNY100HL and wheat germ histones.
Lofton. Hava H; Pränting. Maria M; Thulin. Elisabeth E; Andersson. Dan I DI
Key Findings
- Bacteria develop resistance to LL‑37 rapidly via mutations in pmrB, phoP, and waaY genes
- Resistance often comes with a fitness cost (slower growth) that varies with conditions
- Resistant strains can outcompete wild‑type bacteria at low LL‑37 concentrations, suggesting they can persist in the body
Practical Outcomes
- If you’re considering LL‑37 supplements or topical use, be aware it may promote resistant bacteria. Use it sparingly, combine with other antimicrobial approaches, and monitor for signs of infection or changes in gut flora.
Summary
The study shows that bacteria can quickly become resistant to the natural antimicrobial peptide LL‑37 (and similar peptides) through specific genetic changes. While resistant bugs often grow slower, they can still outgrow normal bacteria at low peptide levels like those found in the body, meaning resistance could stick around. This mainly warns that using LL‑37 as a regular antimicrobial could encourage resistant strains.
Abstract
Antimicrobial peptides (AMPs) represent a potential new class of antimicrobial drugs with potent and broad-spectrum activities. However, knowledge about the mechanisms and rates of resistance development to AMPs and the resulting effects on fitness and cross-resistance is limited. We isolated antimicrobial peptide (AMP) resistant Salmonella typhimurium LT2 mutants by serially passaging several independent bacterial lineages in progressively increasing concentrations of LL-37, CNY100HL and Wheat Germ Histones. Significant AMP resistance developed in 15/18 independent bacterial lineages. Resistance mutations were identified by whole genome sequencing in two-component signal transduction systems (pmrB and phoP) as well as in the LPS core biosynthesis pathway (waaY, also designated rfaY). In most cases, resistance was associated with a reduced fitness, observed as a decreased growth rate, which was dependent on growth conditions and mutation type. Importantly, mutations in waaY decreased bacterial susceptibility to all tested AMPs and the mutant outcompeted the wild type parental strain at AMP concentrations below the MIC for the wild type. Our data suggests that resistance to antimicrobial peptides can develop rapidly through mechanisms that confer cross-resistance to several AMPs. Importantly, AMP-resistant mutants can have a competitive advantage over the wild type strain at AMP concentrations similar to those found near human epithelial cells. These results suggest that resistant mutants could both be selected de novo and maintained by exposure to our own natural repertoire of defence molecules.
Study Information
pubmed
2013
2013-07-23T00:00:00.000Z
10.1371/journal.pone.0068875
63
64